{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:48:08Z","timestamp":1791600488319,"version":"4.3.4"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Vascular toxicity is a frequent adverse effect of current anticancer chemotherapies and often results from endothelial dysfunction. Vascular endothelial growth factor inhibitors (VEGFi), anthracyclines, plant alkaloids, alkylating agents, antimetabolites, and radiation therapy evoke vascular toxicity. These anticancer treatments not only affect tumor vascularization in a beneficial manner, they also damage ECs in the heart. Cardiac ECs have a vital role in cardiovascular functions including hemostasis, inflammatory and coagulation responses, vasculogenesis, and angiogenesis. EC damage can be resulted from capturing angiogenic factors, inhibiting EC proliferation, survival and signal transduction, or altering vascular tone. EC dysfunction accounts for the pathogenesis of myocardial infarction, atherothrombosis, microangiopathies, and hypertension. In this review, we provide a comprehensive overview of the effects of chemotherapeutic agents on vascular toxicity leading to hypertension, microvascular rarefaction thrombosis and atherosclerosis, and affecting drug delivery. We also describe the potential therapeutic approaches such as vascular endothelial growth factor (VEGF)-B and prokineticin receptor-1 agonists to maintain endothelial function during or following treatments with chemotherapeutic agents, without affecting anti-tumor effectiveness.<\/jats:p>","DOI":"10.3389\/fcvm.2021.694711","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T01:54:16Z","timestamp":1627350856000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["Updates on Anticancer Therapy-Mediated Vascular Toxicity and New Horizons in Therapeutic Strategies"],"prefix":"10.3389","volume":"8","author":[{"given":"Po-Yen","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aynura","family":"Mammadova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Benkirane-Jessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"D\u00e9saubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan G.","family":"Nebigil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1161\/ATVBAHA.120.314346","article-title":"Exploring the role of endothelial cell resilience in cardiovascular health and disease","volume":"41","author":"Gao","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.3390\/ijms20184411","article-title":"Vascular endothelial cell biology: an update","volume":"20","author":"Kruger-Genge","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nature06348","article-title":"Bv8 regulates myeloid-cell-dependent tumour angiogenesis","volume":"450","author":"Shojaei","year":"2007","journal-title":"Nature."},{"key":"B4","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","article-title":"Vascular complications of cancer chemotherapy","volume":"32","author":"Cameron","year":"2016","journal-title":"Can J Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"H133","DOI":"10.1152\/ajpheart.00456.2019","article-title":"Doxorubicin contributes to thrombus formation and vascular injury by interfering with platelet function","volume":"319","author":"Lv","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jaccao.2019.06.003","article-title":"Prokineticin receptor-1 signaling inhibits dose- and time-dependent anthracycline-induced cardiovascular toxicity via myocardial and vascular protection","volume":"1","author":"Gasser","year":"2019","journal-title":"JACC Cardiooncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/cvr\/cvz022","article-title":"Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension","volume":"115","author":"Versmissen","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40959-016-0010-6","article-title":"Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents","volume":"2","author":"Morbidelli","year":"2016","journal-title":"Cardiooncology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphys.2018.00167","article-title":"Antineoplastic drug-induced cardiotoxicity: a redox perspective","volume":"9","author":"Varricchi","year":"2018","journal-title":"Front Physiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.cellsig.2012.01.008","article-title":"Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling","volume":"24","author":"Ray","year":"2012","journal-title":"Cell Signal."},{"key":"B11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.21037\/atm.2017.06.27","article-title":"The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox","volume":"5","author":"Moris","year":"2017","journal-title":"Ann Transl Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1476-5381.2010.01196.x","article-title":"Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling","volume":"164","author":"Forstermann","year":"2011","journal-title":"Br J Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.freeradbiomed.2009.06.023","article-title":"Inhibition of mitochondria-dependent apoptosis by 635-nm irradiation in sodium nitroprusside-treated SH-SY5Y cells","volume":"47","author":"Lim","year":"2009","journal-title":"Free Radic Biol Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5080843","DOI":"10.1155\/2019\/5080843","article-title":"Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis","volume":"2019","author":"Su","year":"2019","journal-title":"Oxid Med Cell Longev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.freeradbiomed.2016.10.494","article-title":"Mitochondrial control of apoptosis through modulation of cardiolipin oxidation in hepatocellular carcinoma: a novel link between oxidative stress and cancer","volume":"102","author":"Zhong","year":"2017","journal-title":"Free Radic Biol Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3389\/fcell.2020.00431","article-title":"Interplay between lipid metabolism and autophagy","volume":"8","author":"Xie","year":"2020","journal-title":"Front Cell Dev Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e2006203","DOI":"10.1371\/journal.pbio.2006203","article-title":"Unsolved mysteries: how does lipid peroxidation cause ferroptosis?","volume":"16","author":"Feng","year":"2018","journal-title":"PLoS Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"7156941","DOI":"10.1155\/2017\/7156941","article-title":"Research progress on signaling pathway-associated oxidative stress in endothelial cells","volume":"2017","author":"Liang","year":"2017","journal-title":"Oxid Med Cell Longev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1089\/ars.2007.1989","article-title":"Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension","volume":"10","author":"Schulz","year":"2008","journal-title":"Antioxid Redox Signal."},{"key":"B20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev-med-041316-090622","article-title":"Common cardiovascular complications of cancer therapy: epidemiology, risk prediction, and prevention","volume":"69","author":"Narayan","year":"2018","journal-title":"Annu Rev Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can J Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling - in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.1158\/1078-0432.CCR-13-2056","article-title":"Aflibercept and its role in the treatment of colorectal cancer\u2013letter","volume":"19","author":"Sinicrope","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"VEGFR (Vascular Endothelial Growth Factor Receptor) inhibition induces cardiovascular damage via redox-sensitive processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension."},{"key":"B27","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/cvr\/cvz021","article-title":"Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury","volume":"115","author":"Neves","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1485283","DOI":"10.1155\/2017\/1485283","article-title":"Reactive oxygen species-mediated mechanisms of action of targeted cancer therapy","volume":"2017","author":"Teppo","year":"2017","journal-title":"Oxid Med Cell Longev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1097\/HJH.0000000000000662","article-title":"Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension","volume":"33","author":"Thijs","year":"2015","journal-title":"J Hypertens."},{"key":"B30","doi-asserted-by":"publisher","first-page":"187ra69","DOI":"10.1126\/scitranslmed.3005066","article-title":"Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity","volume":"5","author":"Chintalgattu","year":"2013","journal-title":"Sci Transl Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e015598","DOI":"10.1161\/JAHA.119.015598","article-title":"Anticancer therapy-related increases in arterial stiffness: a systematic review and meta-analysis","volume":"9","author":"Parr","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bbagen.2005.10.012","article-title":"The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction","volume":"1760","author":"Wolf","year":"2006","journal-title":"Biochim Biophys Acta."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3389\/fphar.2019.01531","article-title":"Doxorubicin induces endotheliotoxicity and mitochondrial dysfunction via ROS\/eNOS\/NO pathway","volume":"10","author":"He","year":"2019","journal-title":"Front Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12012-019-09556-3","article-title":"Impact of arterial hypertension on doxorubicin-based chemotherapy-induced subclinical cardiac damage in breast cancer patients","volume":"20","author":"Vaitiekus","year":"2020","journal-title":"Cardiovasc Toxicol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.tiv.2014.12.009","article-title":"Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells","volume":"29","author":"Wojcik","year":"2015","journal-title":"Toxicol In Vitro."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1242\/bio.020362","article-title":"Cardiotoxic drugs herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability","volume":"5","author":"Wilkinson","year":"2016","journal-title":"Biol Open."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications","author":"Sobczuk","year":"2020","journal-title":"Heart Fail Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"8139861","DOI":"10.1155\/2016\/8139861","article-title":"Potential therapeutic strategies for hypertension-exacerbated cardiotoxicity of anticancer drugs","volume":"2016","author":"Kuriakose","year":"2016","journal-title":"Oxid Med Cell Longev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ctrv.2011.09.002","article-title":"Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications","volume":"38","author":"Soultati","year":"2012","journal-title":"Cancer Treat Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s13104-017-2726-2","article-title":"Role of metabolites of cyclophosphamide in cardiotoxicity","volume":"10","author":"Kurauchi","year":"2017","journal-title":"BMC Res Notes."},{"key":"B43","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.ejca.2003.11.026","article-title":"Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy cardiovascular risk factors and signs of vascular damage","volume":"40","author":"de Vos","year":"2004","journal-title":"Eur J Cancer."},{"key":"B44","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fphar.2017.00196","article-title":"Characterization of cardiovascular alterations induced by different chronic cisplatin treatments","volume":"8","author":"Herradon","year":"2017","journal-title":"Front Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/annonc\/mdh150","article-title":"5-Fluorouracil induces arterial vasocontractions","volume":"15","author":"Sudhoff","year":"2004","journal-title":"Ann Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","article-title":"Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines","volume":"21","author":"Shiga","year":"2020","journal-title":"Curr Treat Options Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood."},{"key":"B48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-015-0418-x","article-title":"Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma","volume":"14","author":"Chen","year":"2015","journal-title":"Mol Cancer."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-07-5050","article-title":"Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor","volume":"14","author":"Steeghs","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2040-7378-5-7","article-title":"Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study","volume":"5","author":"Reimann","year":"2013","journal-title":"Exp Transl Stroke Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"80346","DOI":"10.1177\/2324709613480346","article-title":"Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management","volume":"1","author":"Dhesi","year":"2013","journal-title":"J Investig Med High Impact Case Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"34038","DOI":"10.18632\/oncotarget.25954","article-title":"The antiangiogenic action of cisplatin on endothelial cells is mediated through the release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells","volume":"9","author":"Ramer","year":"2018","journal-title":"Oncotarget."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1111\/bph.13543","article-title":"Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(gamma-acac)(DMS)] in a xenograft model of human renal cell carcinoma","volume":"173","author":"Muscella","year":"2016","journal-title":"Br J Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer therapy-associated thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S0049-3848(20)30391-1","article-title":"An overview of thrombotic complications of old and new anticancer drugs","volume":"191","author":"Levi","year":"2020","journal-title":"Thromb Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1161\/01.ATV.0000189309.05924.88","article-title":"Stimulated tissue plasminogen activator release as a marker of endothelial function in humans","volume":"25","author":"Oliver","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.beha.2009.01.001","article-title":"Thrombosis associated with angiogenesis inhibitors","volume":"22","author":"Elice","year":"2009","journal-title":"Best Pract Res Clin Haematol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.semnephrol.2010.09.006","article-title":"Biology of anti-angiogenic therapy-induced thrombotic microangiopathy","volume":"30","author":"Eremina","year":"2010","journal-title":"Semin Nephrol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e101145","DOI":"10.1371\/journal.pone.0101145","article-title":"Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer","volume":"9","author":"Faruque","year":"2014","journal-title":"PLoS ONE."},{"key":"B60","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/jnci\/djk011","article-title":"Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?","volume":"99","author":"Mir","year":"2007","journal-title":"J Natl Cancer Inst."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1158\/1535-7163.MCT-06-0154","article-title":"Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway","volume":"5","author":"Woodley-Cook","year":"2006","journal-title":"Mol Cancer Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000324166","article-title":"Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients","volume":"37","author":"Mukherjee","year":"2010","journal-title":"Pathophysiol Haemost Thromb."},{"key":"B63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/toxsci\/kfr222","article-title":"Doxorubicin-induced platelet procoagulant activities: an important clue for chemotherapy-associated thrombosis","volume":"124","author":"Kim","year":"2011","journal-title":"Toxicol Sci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.bbadis.2015.12.014","article-title":"Mitochondrial aldehyde dehydrogenase protects against doxorubicin cardiotoxicity through a transient receptor potential channel vanilloid 1-mediated mechanism","volume":"1862","author":"Ge","year":"2016","journal-title":"Biochim Biophys Acta."},{"key":"B65","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacbts.2018.06.005","article-title":"Role of endothelium in doxorubicin-induced cardiomyopathy","volume":"3","author":"Luu","year":"2018","journal-title":"JACC Basic Transl Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1158\/1078-0432.CCR-12-3666","article-title":"Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy","volume":"19","author":"Moschella","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/1358863X14568705","article-title":"Approach to chemotherapy-associated thrombosis","volume":"20","author":"Oppelt","year":"2015","journal-title":"Vasc Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"80140","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5603\/CJ.2012.0084","article-title":"5-fluorouracil induced cardiotoxicity: review of the literature","volume":"19","author":"Sorrentino","year":"2012","journal-title":"Cardiol J"},{"key":"B70","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/annonc\/mdn638","article-title":"Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer","volume":"20","author":"Cunningham","year":"2009","journal-title":"Ann Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol Life Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat Rev Cancer."},{"key":"B73","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcancer.2019.08.031","article-title":"Autophagy as a mechanism for anti-angiogenic therapy resistance","volume":"66","author":"Chandra","year":"2020","journal-title":"Semin Cancer Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3389\/fphar.2016.00519","article-title":"Anti-angiogenic therapy in cancer: downsides and new pivots for precision medicine","volume":"7","author":"Lupo","year":"2016","journal-title":"Front Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.placenta.2017.03.010","article-title":"Hypoxia and HIF pathway in cancer and the placenta","volume":"56","author":"Macklin","year":"2017","journal-title":"Placenta."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/ijms19041232","article-title":"Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway","volume":"19","author":"Itatani","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fphys.2014.00075","article-title":"Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis","volume":"5","author":"Riabov","year":"2014","journal-title":"Front Physiol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nm.3291","article-title":"An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy","volume":"19","author":"Chung","year":"2013","journal-title":"Nat Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","article-title":"PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment","volume":"15","author":"Crawford","year":"2009","journal-title":"Cancer Cell."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1126\/science.1127592","article-title":"Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors","volume":"313","author":"Shaked","year":"2006","journal-title":"Science."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.106.652859","article-title":"Endothelial function and dysfunction: testing and clinical relevance","volume":"115","author":"Deanfield","year":"2007","journal-title":"Circulation."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/bph.13517","article-title":"Targeting vascular (endothelial) dysfunction","volume":"174","author":"Daiber","year":"2017","journal-title":"Br J Pharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.thromres.2004.06.045","article-title":"Inflammatory response and the endothelium","volume":"114","author":"Meroni","year":"2004","journal-title":"Thromb Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1590\/S1807-59322009000500015","article-title":"Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis","volume":"64","author":"Landim","year":"2009","journal-title":"Clinics."},{"key":"B85","doi-asserted-by":"publisher","first-page":"9759735","DOI":"10.1155\/2017\/9759735","article-title":"Markers and biomarkers of endothelium: when something is rotten in the state","volume":"2017","author":"Goncharov","year":"2017","journal-title":"Oxid Med Cell Longev."},{"key":"B86","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3791\/52339","article-title":"A methodological approach to non-invasive assessments of vascular function and morphology","volume":"45","author":"Sandoo","year":"2015","journal-title":"J Vis Exp."},{"key":"B87","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1124\/jpet.109.159178","article-title":"Sulfhydryl angiotensin-converting enzyme inhibitor promotes endothelial cell survival through nitric-oxide synthase, fibroblast growth factor-2, and telomerase cross-talk","volume":"332","author":"Donnini","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1124\/jpet.114.218404","article-title":"Protective effects of novel metal-nonoates on the cellular components of the vascular system","volume":"351","author":"Monti","year":"2014","journal-title":"J Pharmacol Exp Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1242\/jcs.117184","article-title":"Mitochondrial aldehyde dehydrogenase-2 activation prevents beta-amyloid-induced endothelial cell dysfunction and restores angiogenesis","volume":"126","author":"Solito","year":"2013","journal-title":"J Cell Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/stem.1206","article-title":"Umbilical cord blood-derived aldehyde dehydrogenase-expressing progenitor cells promote recovery from acute ischemic injury","volume":"30","author":"Putman","year":"2012","journal-title":"Stem Cells."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00280-013-2260-4","article-title":"The role of antioxidants in the era of cardiooncology","volume":"72","author":"Vincent","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1158\/1078-0432.CCR-20-1967","article-title":"Statins as anticancer agents in the era of precision medicine","volume":"26","author":"Longo","year":"2020","journal-title":"Clin Cancer Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"13144","DOI":"10.1073\/pnas.1616168113","article-title":"VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection","volume":"113","author":"Rasanen","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B94","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.tcm.2009.04.007","article-title":"Prokineticin receptors in cardiovascular function: foe or friend?","volume":"19","author":"Nebigil","year":"2009","journal-title":"Trends Cardiovasc Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1096\/fj.07-8116com","article-title":"The prokineticin receptor-1 (GPR73) promotes cardiomyocyte survival and angiogenesis","volume":"21","author":"Urayama","year":"2007","journal-title":"FASEB J."},{"key":"B96","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/jdb8040032","article-title":"Role of Prokineticin Receptor-1 in Epicardial Progenitor Cells","volume":"8","author":"Nguyen","year":"2020","journal-title":"J Dev Biol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e81175","DOI":"10.1371\/journal.pone.0081175","article-title":"Prokineticin receptor 1 as a novel suppressor of preadipocyte proliferation and differentiation to control obesity","volume":"8","author":"Szatkowski","year":"2013","journal-title":"PLoS ONE."},{"key":"B98","doi-asserted-by":"publisher","first-page":"25541","DOI":"10.1038\/srep25541","article-title":"Prokineticin receptor-1 signaling promotes epicardial to mesenchymal transition during heart development","volume":"6","author":"Arora","year":"2016","journal-title":"Sci Rep."},{"key":"B99","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/cvr\/cvn251","article-title":"Transgenic myocardial overexpression of prokineticin receptor-2 (GPR73b) induces hypertrophy and capillary vessel leakage","volume":"81","author":"Urayama","year":"2009","journal-title":"Cardiovasc Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1161\/HYPERTENSIONAHA.120.16808","article-title":"Pressure overload-mediated sustained PKR2 (Prokineticin-2 Receptor) signaling in cardiomyocytes contributes to cardiac hypertrophy and endotheliopathies","volume":"77","author":"Demir","year":"2021","journal-title":"Hypertension."},{"key":"B101","doi-asserted-by":"publisher","first-page":"H844","DOI":"10.1152\/ajpheart.00898.2009","article-title":"Divergent roles of prokineticin receptors in the endothelial cells: angiogenesis and fenestration","volume":"298","author":"Guilini","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e0121027","DOI":"10.1371\/journal.pone.0121027","article-title":"Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1","volume":"10","author":"Gasser","year":"2015","journal-title":"PLoS ONE."},{"key":"B103","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"Abdol Razak","year":"2018","journal-title":"Cancers."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e000665","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J Am Heart Assoc."},{"key":"B105","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fcvm.2019.00194","article-title":"Targeting GPCRs against cardiotoxicity induced by anticancer treatments","volume":"6","author":"Audebrand","year":"2019","journal-title":"Front Cardiovasc Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.694711\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T01:54:21Z","timestamp":1627350861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.694711\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":105,"alternative-id":["10.3389\/fcvm.2021.694711"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.694711","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"article-number":"694711"}}